close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axonex AI Group Limited - Class A Ordinary Shares (NQ:AXNX)

0.5999 -0.1101 (-15.51%)
Delayed Quote Updated: 1:50 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axonex AI Group Limited - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year ↗
Biotech isn't the only place to make money in health care this year. 
Via Investor's Business Daily
News headline image
Piper Sandler Maintains Overweight Rating for Axonics: Here's What You Need To Know ↗
Piper Sandler has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $82.00 to $84.00. Shares of Axonics are trading down 1.5% over the last 24 hours, at... 
Via Benzinga
News headline image
Where Axonics Stands With Analysts ↗
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Is This Medical Gear Maker Ready To Continue Its Rally?
Medical gear maker Axonics rallied to a new high after an announcement that it entered the Canadian market. Is it set for bigger gains on strong revenue growth? 
Via MarketBeat
Topics Intellectual Property
News headline image
Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
News headline image
What 9 Analyst Ratings Have To Say About Axonics ↗
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Analyst Ratings for Axonics ↗
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Axonics® to Participate in September Investor Conferences
From Axonics, Inc.
Via Business Wire
News headline image
Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
From Axonics, Inc.
Via Business Wire
News headline image
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock
From Axonics, Inc.
Via Business Wire
News headline image
Axonics® Announces Pricing of Public Offering of Common Stock
From Axonics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is... 
Via Benzinga
News headline image
Axonics® Announces Proposed Public Offering of Common Stock
From Axonics, Inc.
Via Business Wire
News headline image
Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance ↗
 
Via Benzinga
News headline image
Morgan Stanley Maintains Overweight Rating for Axonics: Here's What You Need To Know ↗
Morgan Stanley has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $73.00 to $80.00. Shares of Axonics are trading up 5.7% over the last 24 hours, at... 
Via Benzinga
News headline image
Recap: Axonics Q2 Earnings ↗
Axonics (NASDAQ:AXNX) reported its Q2 earnings results on Monday, August 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by... 
Via Benzinga
News headline image
Axonics® Reports Second Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
News headline image
Axonics® to Report Second Quarter 2022 Financial Results on August 1
From Axonics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 1, 2022 ↗
Companies Reporting Before The Bell • Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter. 
Via Benzinga
News headline image
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator
From Axonics, Inc.
Via Business Wire
News headline image
Axonics® Reports First Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Axonics® to Participate in BofA Securities 2022 Healthcare Conference
From Axonics, Inc.
Via Business Wire
News headline image
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million. 
Via Benzinga
News headline image
Axonics® to Report First Quarter 2022 Financial Results on May 5
From Axonics, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Axonics® Launches Direct to Consumer Television Advertising Campaign
From Axonics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
News headline image
FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System ↗
The FDA has approved Axonics Inc's (NASDAQ: AXNX) recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). The Axonics F15 recharge-free... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.